Special Issue "Extracellular Vesicles (EVs) in Formulation Development, Pre-clinical and Clinical Stages"

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Nanotechnology Applications in Bioengineering".

Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 2422

Special Issue Editors

Department of Immunology and Microbiology, College of Medicine, University of Texas Rio Grade Valley, McAllen, TX 78503, USA
Interests: cancer therapy; drug delivery; drug targeting; infectious disease; micelle; nanoparticles; nanotechnology; polymers; targeted therapies; HIV; antibody engineering; antibody–drug conjugates
Special Issues, Collections and Topics in MDPI journals
Department of Oncology-Pathology, Karolinska Institutet, SE-171 77 Stockholm, Sweden
Interests: autophagy; protein homeostasis and degradation; cell death; extracellular vesicles

Special Issue Information

Dear Colleagues,

Extracellular vesicles (EVs) are a group of natural carriers that may have the capability delivered delivering active pharmaceutical ingredients (APIs) for better therapeutic results. EVs may help APIs bypass certain delivery barriers to improve drug concentration at the target site(s). Such strategies may also reduce systemic side effects and may allow for higher dosing for patients.

In this Special Issue, we are calling for manuscripts covering every possible step in a product cycle, starting from EV production and purification to final EV drug formulation as well as pre-clinical/clinical trials. We also encourage manuscripts to discuss potential regulatory affairs and quality assurance, as peer-reviewed articles are one critical source for regulatory agencies, such as the US FDA, to help their draft guidelines for the industry.

There are no restrictions as to which medical conditions can be discussed. Manuscripts must cover at least one of the following aspects to be eligible for this Special Issue:

  • The production and purification of EVs without any APIs. The inclusion of in-process quality control and characterization tests as well as final tests is encouraged.
  • Formulation processing development using EVs to deliver APIs. The inclusion of in-process testing to show the encapsulation/affiliation/conjugation of the APIs is encouraged as they are critical for future development.
  • Formulation processing development using EVs to deliver APIs using cell line/animal models in pre-clinical stages to show significant improvements in drug delivery.
  • Any clinical trials using EVs to deliver APIs at all stages.
  • Regulatory affairs and quality assurance (RAQA) to discuss/help regulatory agencies provide guidance for the industry.
  • Any other aspects that authors are interested in and willing to discuss in advance with the editorial team before drafting.

We are looking forward to receiving your manuscripts, and we appreciate your contributions.

Dr. Murali Mohan Yallapu
Dr. Hao Shi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • extracellular vesicles (EVs)
  • nanoformulations
  • formulation development processing
  • clinical trials
  • regulatory affairs and quality assurance (RAQA)

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


12 pages, 1026 KiB  
Targeting Capabilities of Native and Bioengineered Extracellular Vesicles for Drug Delivery
Bioengineering 2022, 9(10), 496; https://doi.org/10.3390/bioengineering9100496 - 22 Sep 2022
Cited by 8 | Viewed by 1896
Extracellular vesicles (EVs) are highly promising as drug delivery vehicles due to their nanoscale size, stability and biocompatibility. EVs possess natural targeting abilities and are known to traverse long distances to reach their target cells. This long-range organotropism and the ability to penetrate [...] Read more.
Extracellular vesicles (EVs) are highly promising as drug delivery vehicles due to their nanoscale size, stability and biocompatibility. EVs possess natural targeting abilities and are known to traverse long distances to reach their target cells. This long-range organotropism and the ability to penetrate hard-to-reach tissues, including the brain, have sparked interest in using EVs for the targeted delivery of pharmaceuticals. In addition, EVs can be readily harvested from an individual’s biofluids, making them especially suitable for personalized medicine applications. However, the targeting abilities of unmodified EVs have proven to be insufficient for clinical applications. Multiple attempts have been made to bioengineer EVs to fine-tune their on-target binding. Here, we summarize the current state of knowledge on the natural targeting abilities of native EVs. We also critically discuss the strategies to functionalize EV surfaces for superior long-distance targeting of specific tissues and cells. Finally, we review the challenges in achieving specific on-target binding of EV nanocarriers. Full article
Show Figures

Figure 1

Back to TopTop